These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

88 related items for PubMed ID: 18756437

  • 1. [Haematologic adverse effects of treatment of chronic viral hepatitis B and C].
    Porubcin S, Schréter I, Kristian P, Pellová A.
    Klin Mikrobiol Infekc Lek; 2008 Apr; 14(2):74-8. PubMed ID: 18756437
    [Abstract] [Full Text] [Related]

  • 2. Cytopenias during treatment of HIV-HCV-coinfection with pegylated interferon and ribavirin: safety analysis of the OPERA study.
    Pontali E, Angeli E, Cattelan AM, Maida I, Nasta P, Verucchi G, Caputo A, Iannacone C, Puoti M.
    Antivir Ther; 2015 Apr; 20(1):39-48. PubMed ID: 24831457
    [Abstract] [Full Text] [Related]

  • 3. Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients.
    Mira JA, López-Cortés LF, Merino D, Arizcorreta-Yarza A, Rivero A, Collado A, Ríos-Villegas MJ, González-Serrano M, Torres-Tortoso M, Macías J, Valera-Bestard B, Fernández-Fuertes E, Girón-González JA, Lozano F, Pineda JA, Grupo para el Estudio de las Hepatitis Viricas de la Sociedad Andaluza de Enfermedades Infecciosas.
    Antivir Ther; 2007 Apr; 12(8):1225-35. PubMed ID: 18240862
    [Abstract] [Full Text] [Related]

  • 4. Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C.
    Nudo CG, Wong P, Hilzenrat N, Deschênes M.
    Can J Gastroenterol; 2006 Sep; 20(9):589-92. PubMed ID: 17001400
    [Abstract] [Full Text] [Related]

  • 5. Erythropoietin treatment is associated with more severe thrombocytopenia in patients with chronic hepatitis C undergoing antiviral therapy.
    Homoncik M, Sieghart W, Formann E, Schmid M, Ferenci P, Gangl A, Jilma B, Peck-Radosavljevic M.
    Am J Gastroenterol; 2006 Oct; 101(10):2275-82. PubMed ID: 17032193
    [Abstract] [Full Text] [Related]

  • 6. Defective synthesis of granulocyte-colony stimulating factor in pegylated interferon-alpha treated chronic hepatitis C patients with declining leukocyte counts.
    Durante-Mangoni E, Iardino P, Utili R, Adinolfi LE, Ruggiero G.
    Antivir Ther; 2006 Oct; 11(5):637-40. PubMed ID: 16964833
    [Abstract] [Full Text] [Related]

  • 7. Granulocyte colony-stimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy.
    Koirala J, Gandotra SD, Rao S, Sangwan G, Mushtaq A, Htwe TH, Adamski A, Blessman D, Khardori NM.
    J Viral Hepat; 2007 Nov; 14(11):782-7. PubMed ID: 17927614
    [Abstract] [Full Text] [Related]

  • 8. Adverse effects during the treatment with pegylated interferon and ribavirin in children with chronic hepatitis C.
    Kowala-Piaskowska A, Mozer-Lisewska I, Figlerowicz M, Słuzewski W.
    Pharmacoepidemiol Drug Saf; 2007 Oct; 16(10):1095-103. PubMed ID: 17724740
    [Abstract] [Full Text] [Related]

  • 9. Virological response and safety outcomes in therapy-nai ve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study.
    Gish RG, Arora S, Rajender Reddy K, Nelson DR, O'Brien C, Xu Y, Murphy B.
    J Hepatol; 2007 Jul; 47(1):51-9. PubMed ID: 17470380
    [Abstract] [Full Text] [Related]

  • 10. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.
    Lee SD, Yu ML, Cheng PN, Lai MY, Chao YC, Hwang SJ, Chang WY, Chang TT, Hsieh TY, Liu CJ, Chen DS.
    J Viral Hepat; 2005 May; 12(3):283-91. PubMed ID: 15850469
    [Abstract] [Full Text] [Related]

  • 11. Role of epoetin alfa in maintaining ribavirin dose.
    Afdhal NH.
    Gastroenterol Clin North Am; 2004 Mar; 33(1 Suppl):S25-35. PubMed ID: 15081101
    [Abstract] [Full Text] [Related]

  • 12. Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia.
    Ong JP, Younossi ZM.
    Cleve Clin J Med; 2004 May; 71 Suppl 3():S17-21. PubMed ID: 15468613
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Hepatic iron accumulation is associated with disease progression and resistance to interferon/ribavirin combination therapy in chronic hepatitis C.
    Fujita N, Sugimoto R, Urawa N, Araki J, Mifuji R, Yamamoto M, Horiike S, Tanaka H, Iwasa M, Kobayashi Y, Adachi Y, Kaito M.
    J Gastroenterol Hepatol; 2007 Nov; 22(11):1886-93. PubMed ID: 17914965
    [Abstract] [Full Text] [Related]

  • 16. Feasibility of pegylated interferon and ribavirin in hepatitis C-related cirrhosis with neutropenia or thrombocytopenia.
    Iacobellis A, Cozzolongo R, Minerva N, Valvano MR, Niro GA, Fontana R, Palmieri O, Ippolito A, Andriulli A.
    Dig Liver Dis; 2014 Jul; 46(7):621-4. PubMed ID: 24675038
    [Abstract] [Full Text] [Related]

  • 17. [Experiences in antiviral treatment of chronic viral hepatitis B and C in Hungary (1998-2004)].
    Pár A, Tornai I, Szalay F.
    Orv Hetil; 2007 May 06; 148(18):819-26. PubMed ID: 17468063
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. An assessment of serum leptin levels in patients with chronic viral hepatitis: a prospective study.
    Manolakopoulos S, Bethanis S, Liapi C, Stripeli F, Sklavos P, Margeli A, Christidou A, Katsanika A, Vogiatzakis E, Tzourmakliotis D, Theocharis S.
    BMC Gastroenterol; 2007 May 31; 7():17. PubMed ID: 17540037
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.